This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Toso, J. F. Articles by Rosenberg, S. A. Search for Related Content PubMed PubMed Citation Articles by Toso, J. F. Articles by Rosenberg, S. A. Social Bookmarking                            What's this?

Phase I Study of the Intravenous Administration of Attenuated Salmonella typhimurium to Patients With Metastatic Melanoma

From the Surgery Branch, Center for Cancer Research, National Cancer Institute; Clinical Pathology Department, Microbiology Service, National Institutes of Health, Bethesda, MD; and Vion Pharmaceuticals, New Haven, CT.

Address reprint requests to Steven A. Rosenberg, MD, PhD, Surgery Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Building 10, Room 2B42, Bethesda, MD 20892; email: Steven_Rosenberg{at}nih.gov

PURPOSE: A strain of Salmonella typhimurium (VNP20009), attenuated by chromosomal deletion of the purI and msbB genes, was found to target to tumor and inhibit tumor growth in mice. These findings led to the present phase I study of the intravenous infusion of VNP20009 to patients with metastatic cancer.

PATIENTS AND METHODS: In cohorts consisting of three to six patients, 24 patients with metastatic melanoma and one patient with metastatic renal cell carcinoma received 30-minute intravenous bolus infusions containing 10⁶ to 10⁹ cfu/m² of VNP20009. Patients were evaluated for dose-related toxicities, selective replication within tumors, and antitumor effects.

RESULTS: The maximum-tolerated dose was 3 x 10⁸ cfu/m². Dose-limiting toxicity was observed in patients receiving 1 x 10⁹ cfu/m², which included thrombocytopenia, anemia, persistent bacteremia, hyperbilirubinemia, diarrhea, vomiting, nausea, elevated alkaline phosphatase, and hypophosphatemia. VNP20009 induced a dose-related increase in the circulation of proinflammatory cytokines, such as interleukin (IL)-1ß, tumor necrosis factor alpha, IL-6, and IL-12. Focal tumor colonization was observed in two patients receiving 1 x 10⁹ cfu/m² and in one patient receiving 3 x 10⁸ cfu/m². None of the patients experienced objective tumor regression, including those patients with colonized tumors.

CONCLUSION: The VNP20009 strain of Salmonella typhimurium can be safely administered to patients, and at the highest tolerated dose, some tumor colonization was observed. No antitumor effects were seen, and additional studies are required to reduce dose-related toxicity and improve tumor localization.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. Loeffler, G. Le'Negrate, M. Krajewska, and J. C. Reed Inhibition of Tumor Growth Using Salmonella Expressing Fas Ligand J Natl Cancer Inst, August 6, 2008; 100(15): 1113 - 1116. [Abstract] [Full Text] [PDF]

				F. Friedlos, P. Lehouritis, L. Ogilvie, D. Hedley, L. Davies, D. Bermudes, I. King, J. Martin, R. Marais, and C. J. Springer Attenuated Salmonella Targets Prodrug Activating Enzyme Carboxypeptidase G2 to Mouse Melanoma and Human Breast and Colon Carcinomas for Effective Suicide Gene Therapy Clin. Cancer Res., July 1, 2008; 14(13): 4259 - 4266. [Abstract] [Full Text] [PDF]

				N. Arrach, M. Zhao, S. Porwollik, R. M. Hoffman, and M. McClelland Salmonella Promoters Preferentially Activated Inside Tumors Cancer Res., June 15, 2008; 68(12): 4827 - 4832. [Abstract] [Full Text] [PDF]

				P. Brader, J. Stritzker, C. C. Riedl, P. Zanzonico, S. Cai, E. M. Burnazi, E.R. Ghani, H. Hricak, A. A. Szalay, Y. Fong, et al. Escherichia coli Nissle 1917 Facilitates Tumor Detection by Positron Emission Tomography and Optical Imaging Clin. Cancer Res., April 15, 2008; 14(8): 2295 - 2302. [Abstract] [Full Text] [PDF]

				M. Loeffler, G. Le'Negrate, M. Krajewska, and J. C. Reed Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth PNAS, July 31, 2007; 104(31): 12879 - 12883. [Abstract] [Full Text] [PDF]

				M. Zhao, J. Geller, H. Ma, M. Yang, S. Penman, and R. M. Hoffman Monotherapy with a tumor-targeting mutant of Salmonella typhimurium cures orthotopic metastatic mouse models of human prostate cancer PNAS, June 12, 2007; 104(24): 10170 - 10174. [Abstract] [Full Text] [PDF]

				M. Zhao, M. Yang, H. Ma, X. Li, X. Tan, S. Li, Z. Yang, and R. M. Hoffman Targeted therapy with a salmonella typhimurium leucine-arginine auxotroph cures orthotopic human breast tumors in nude mice. Cancer Res., August 1, 2006; 66(15): 7647 - 7652. [Abstract] [Full Text] [PDF]

				L. A. Diaz Jr., I. Cheong, C. A. Foss, X. Zhang, B. A. Peters, N. Agrawal, C. Bettegowda, B. Karim, G. Liu, K. Khan, et al. Pharmacologic and Toxicologic Evaluation of C. novyi-NT Spores Toxicol. Sci., December 1, 2005; 88(2): 562 - 575. [Abstract] [Full Text] [PDF]

				D. H. Thamm, I. D. Kurzman, I. King, Z. Li, M. Sznol, R. R. Dubielzig, D. M. Vail, and E. G. MacEwen Systemic Administration of an Attenuated, Tumor-Targeting Salmonella typhimurium to Dogs with Spontaneous Neoplasia: Phase I Evaluation Clin. Cancer Res., July 1, 2005; 11(13): 4827 - 4834. [Abstract] [Full Text] [PDF]

				F. Avogadri, C. Martinoli, L. Petrovska, C. Chiodoni, P. Transidico, V. Bronte, R. Longhi, M. P. Colombo, G. Dougan, and M. Rescigno Cancer Immunotherapy Based on Killing of Salmonella-Infected Tumor Cells Cancer Res., May 1, 2005; 65(9): 3920 - 3927. [Abstract] [Full Text] [PDF]

				M. Zhao, M. Yang, X.-M. Li, P. Jiang, E. Baranov, S. Li, M. Xu, S. Penman, and R. M. Hoffman Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium PNAS, January 18, 2005; 102(3): 755 - 760. [Abstract] [Full Text] [PDF]

				R. Kalupahana, A. R. Emilianus, D. Maskell, and B. Blacklaws Salmonella enterica Serovar Typhimurium Expressing Mutant Lipid A with Decreased Endotoxicity Causes Maturation of Murine Dendritic Cells Infect. Immun., November 1, 2003; 71(11): 6132 - 6140. [Abstract] [Full Text] [PDF]

				N. S. Forbes, L. L. Munn, D. Fukumura, and R. K. Jain Sparse Initial Entrapment of Systemically Injected Salmonella typhimurium Leads to Heterogeneous Accumulation within Tumors Cancer Res., September 1, 2003; 63(17): 5188 - 5193. [Abstract] [Full Text] [PDF]